Clinical Trials Logo

Tuberculosis (TB) clinical trials

View clinical trials related to Tuberculosis (TB).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03929705 Completed - Tuberculosis (TB) Clinical Trials

Assessing the Ability of the T-SPOT®.TB Test

IQ
Start date: May 2, 2019
Phase:
Study type: Observational

The primary objective of this clinical research study is to demonstrate performance of the normalized TB specific lymphocyte response in identifying patients with active TB disease. The secondary exploratory objective is to demonstrate that active TB cannot be identified using an antigen-to-mitogen ratio derived from an ELISA-based IGRA.

NCT ID: NCT01879163 Completed - Tuberculosis (TB) Clinical Trials

Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults

Start date: July 2013
Phase: Phase 1
Study type: Interventional

This is a Phase I trial to evaluate the safety and immunogenicity of MVA85A-IMX313 vaccination compared to MVA85A vaccination, in BCG vaccinated adults.

NCT ID: NCT00730795 Completed - Tuberculosis (TB) Clinical Trials

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults

Start date: January 2004
Phase: Phase 1
Study type: Interventional

This Phase I study will evaluate the safety and immunogenicity of two doses GSK Biologicals' candidate TB vaccine (692342) according to a 0, 1, 2 months schedule in PPD-negative adults.

NCT ID: NCT00600782 Completed - Tuberculosis (TB) Clinical Trials

Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region

Start date: February 5, 2008
Phase: Phase 2
Study type: Interventional

This study will assess the safety and immunogenicity of a GSK Biologicals' candidate TB vaccine administered at 0, 1 months to healthy adults living in a TB-endemic region. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

NCT ID: NCT00291889 Completed - Tuberculosis (TB) Clinical Trials

Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.

Start date: July 2004
Phase: Phase 1
Study type: Interventional

Vaccination against tuberculosis (TB) /healthy PPD-negative adults aged 18 to 45 years.Three doses of primary vaccination followed by a booster dose after completion of primary vaccination course. Booster vaccination will be given only to subjects receiving the candidate tuberculosis vaccines and not to the subjects receiving active comparators or control.

NCT ID: NCT00146744 Completed - Tuberculosis (TB) Clinical Trials

Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-positive Adults

Start date: July 2005
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety, reactogenicity and immunogenicity of Mtb72F/AS02A in healthy European volunteers who are PPD-positive either via previous vaccination with BCG and/or conversion to PPD positivity through exposure to Mycobacterium tuberculosis.